KIRKLAND, Wash., Nov. 10 /PRNewswire/ -- ProteoTech, Inc. announced today that the Company Chief Executive Officer, Steve Runnels, will present an overview of ProteoTech's drug development pipeline, at the Rodman & Renshaw's 10th Annual Healthcare Conference on Tuesday, November 11th, 2008 at 9:55 a.m. EST at the New York Palace Hotel, 455 Madison Avenue, New York, NY.
About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics and diagnostics targeting amyloid diseases. With over 165 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1(R) for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late stage pre-clinical development with Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere(TM) as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at http://www.proteotech.com or contact us at info@proteotech.com.
CONTACT: ProteoTech, Inc., +1-425-823-0400, info@proteotech.com
Web site: http://www.proteotech.com/
